An Evaluation of MiniMed™ 780G System Performance in Childhood: A Single Center Experience from Turkey

Elif Eviz; Yesiltepe Mutlu R. Gul; Ecem Can; Tugba Gokce; Serra Muradoglu; Sukru Hatun

Introduction: Automated insulin delivery systems provide significant improvement in the time in range(TIR) centered diabetes care. This study analyzes the real-word performance of Minimed 780G™system-Advanced Hybrid Closed Loop(AHCL) in children from a single center.

Methods: Of the 93 children started to use AHCL between January 2021 and April 2022, 64 whose data could be accessed were included. 3,6,9 and 12 month-data were analyzed in terms of the proportion of users achieving recommended glucose management indicator (GMI<7.0%), TIR (70-180 mg/dL >70%) and time below range(TBR<5%) goals. In a second analysis, data of the children previously treated with multiple daily injections (MDI) (group-1, n:23) and with insulin pumps (group-2, n:39) were analyzed regarding glycemic profile before and after AHCL.

Results: At the baseline mean TIR, TBR<70 and HbA1c were 72.7±11.7%, 4±4.5% and 7.3±0.9% while they were 80.1±8.7%, 3.4±3% and 6.8±0.8% respectively at 3-month. TIR increased by 7.4% at 3-month, compared to baseline (P:0.001). At 3-month, 88% of the participants achieved TIR>70% goal, 80.4% achieved TIR >70% and GMI<7% and TBR<5% goals. No significant difference was noted between 3-6-9 and 12th month TIR percentages (80%, 79%, 81%, 82%, p:0.122). In group-1 and group-2, the increase in TIR from baseline to 3-month were 13%, 6%, respectively (P1:0.01; p2:0.017). The increase in TIR at 3-month in Group-1 was significantly higher than in Group-2 (P 0.014).

Table 1. Glycemic metric values at 1-year follow-up before and after AHCL use
	Baseline(n:33)	3-month(n:58)	6-month(n: 41)	9-month (n:34)	12-month (n:24)
Automode(%)	N/A	96.3±8.1	95.6±6.9	97±4	95.2±7.7
TIR(%)	72.7±11.7	80.1±8.7	79.1±9.2	81.4±7.8	82.1±7
TAR>180(%)	18.8±8.4	13.8±6.5	15±6.6	13.5±5.3	13.3±5.3
TAR >250(%)	4.2±4.6	2.6±2.8	2.8±2.7	2.5±2.8	2±2.2
TBR<70(%)	4±4.5	3.4±3	2.4±2.2	2.2±1.7	2.5±1.8
CV(%)	33.7±6.1	33.7±5.1	33±4.2	32.7±6	31.8±7.3
GMI(%)	N/A	7±3.8	6.6±0.2	6.5±0.2	6.5±0.28
HbA1c (%)	7.3±0.9	6.8±0.8	6.8±0.4	7.1±0.8	6.8±0.5
TIR of>%70	60	87.7	82.9	94.1	95.8
3 goals (TIR>70%+GMI<7%+TBR<5)	N/A	80.4	77.5	85.3	87
*Linear regression model was used in the analysis of the data

Conclusion: AHCL is a reliable system for achieving and maintaining glycemic goals, mainly TIR >70%goal in children. The improvement is more prominent in the children previously treated with MDI.

ESPE Abstracts

P1-50